Leukemia, Myeloid, Acute

• 

  Subject Areas on Research

  • 'Hypopyon' in the anterior chamber: unilateral ocular relapse of acute myeloid leukaemia in a 2-year-old girl. 
  • 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. 
  • A Cohort Study of Patient-Reported Outcomes and Healthcare Utilization in Acute Myeloid Leukemia Patients Receiving Active Cancer Therapy in the Last Six Months of Life. 
  • A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. 
  • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. 
  • A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. 
  • A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. 
  • A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. 
  • A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. 
  • A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. 
  • A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. 
  • A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. 
  • A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. 
  • A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. 
  • A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. 
  • Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. 
  • Actigraphy assessment of sleep quality among patients with acute myeloid leukaemia during induction chemotherapy. 
  • Acute Leukemia Patients' Needs: Qualitative Findings and Opportunities for Early Palliative Care. 
  • Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer. 
  • Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Acute leukemia in children. 
  • Acute myeloblastic leukemia in paroxysmal nocturnal hemoglobinuria. Evidence of evolution from the abnormal paroxysmal nocturnal hemoglobinuria clone. 
  • Acute myelogenous leukemia associated with Ollier disease. 
  • Acute myelogenous leukemia subsequent to therapy for a different neoplasm: clinical features and response to therapy. 
  • Acute myeloid leukemia and myelodysplastic syndromes in older adults. 
  • Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. 
  • Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. 
  • Acute myeloid leukemia, version 2.2013. 
  • Acute myeloid leukemia. 
  • Acute myeloid leukemia. 
  • Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse. 
  • Adriamycin in the treatment of childhood acute leukemia. A Southwest Oncology Group study. 
  • Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. 
  • Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. 
  • Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. 
  • Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. 
  • Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. 
  • An exploratory study of environmental and medical factors potentially related to childhood cancer. 
  • An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. 
  • Analysis of the presenting features of adult acute leukemia: the French-American-British classification. 
  • Aortobronchial fistula in a pediatric patient with massive hemoptysis: treatment by means of an aortic endograft. 
  • Are results of targeted gene sequencing ready to be used for clinical decision making for patients with acute myelogenous leukemia? 
  • Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. 
  • Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. 
  • Asymmetric anterior uveitis as a delayed complication of treatment with systemic high-dose cytosine-arabinoside: a case report and literature review. 
  • Auto-SCT for AML in second remission: CALGB study 9620. 
  • Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. 
  • Autologous marrow transplantation for patients with acute myelogenous leukemia--a preliminary report. 
  • Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. 
  • BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. 
  • Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. 
  • Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. 
  • Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. 
  • Biological Role and Therapeutic Potential of IDH Mutations in Cancer. 
  • Biomarker clustering to address correlations in proteomic data. 
  • Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. 
  • Busulfan and metronidazole: an often forgotten but significant drug interaction. 
  • Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. 
  • Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. 
  • CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. 
  • CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia. 
  • Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability. 
  • Candidal splenic abscesses. 
  • Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. 
  • Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation. 
  • Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1. 
  • Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. 
  • Clinical implications of aneuploid cytogenetic profiles in adult acute leukemia. 
  • Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. 
  • Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia. 
  • Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. 
  • Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. 
  • Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. 
  • Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. 
  • Comparative trials of chemotherapy and bone marrow transplantation in acute nonlymphocytic leukemia. 
  • Comparison of in vitro and in vivo differentiation of myeloblastic leukemia of the RFM/Un mouse. 
  • Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. 
  • Concurrent acute myeloid leukemia with inv(16)(p13.1q22) and chronic lymphocytic leukemia: molecular evidence of two separate diseases. 
  • Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. 
  • Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. 
  • Continuous-infusion diaziquone in acute myeloid leukemia: a Southeastern Cancer Study Group trial. 
  • Cooperative effects of gamma interferon and 1-alpha,25-dihydroxyvitamin D3 in inducing differentiation of human promyelocytic leukemia (HL-60) cells. 
  • Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia. 
  • Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. 
  • Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. 
  • Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. 
  • Cytogenetic studies and their clinical correlates in adults with acute leukemia. 
  • Cytoprotective effects of hematopoietic growth factors on primary human acute myeloid leukemias are not mediated through changes in BCL-2, bax, or p21WAF1/CIP1. 
  • Data monitoring and large apparent treatment effects. 
  • Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson. 
  • Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. 
  • Dendriform pulmonary ossification. Report of two cases with unique findings. 
  • Detection of both T-cell and Ia-like antigens on cells from patients with acute myelomonocytic leukemia and chronic myelogenous leukemia in blast crisis. 
  • Development of bullous pemphigoid after allogeneic bone marrow transplantation. Report of a case. 
  • Differentiation of normal marrow and HL60 cells induced by antithymocyte globulin. 
  • Dissociation of opsonized particle phagocytosis and respiratory burst activity in an Epstein-Barr virus-infected myeloid cell line. 
  • Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. 
  • Donor cell leukemia developing six years after marrow grafting for acute leukemia. 
  • Donor cell leukemia in umbilical cord blood transplant patients: a case study and literature review highlighting the importance of molecular engraftment analysis. 
  • Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. 
  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. 
  • Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. 
  • Dynamic assessment of quality of life after autologous bone marrow transplantation. 
  • Early deaths in newly diagnosed cases of pediatric acute leukemia: a Southwest Oncology Group Study. 
  • Ecthyma gangrenosum of the scrotum: a case report. 
  • Ectopic expression of transcription factor NF-E2 alters the phenotype of erythroid and monoblastoid cells. 
  • Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. 
  • Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia. 
  • Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. 
  • Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. 
  • Effects of treatment regimens on post marrow transplant relapse. 
  • Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. 
  • Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. 
  • Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. 
  • Elastomeric negative acoustic contrast particles for capture, acoustophoretic transport, and confinement of cells in microfluidic systems. 
  • Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. 
  • Energy dispersive x-ray detection of thorium dioxide. 
  • Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. 
  • Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials. 
  • Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. 
  • Expert insights into the contemporary management of older adults with acute myeloid leukemia. 
  • Expression and prognostic impact of lncRNAs in acute myeloid leukemia. 
  • Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. 
  • FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. 
  • Facilitated light microscopic cytochemical diagnosis of acute myelogenous leukemia. 
  • Factors and inhibitors of blood coagulation and fibrinolysis in acute nonlymphoblastic leukaemia. 
  • Factors influencing survival in pediatric acute leukemia. The SWCCSG experience, 1958-1970. 
  • Fanconi anemia gene variants in therapy-related myeloid neoplasms. 
  • Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. 
  • Ferritin heavy chain-mediated iron homeostasis and subsequent increased reactive oxygen species production are essential for epithelial-mesenchymal transition. 
  • Fever in acute myelogenous leukemia. 
  • Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. 
  • Flt3 is dispensable to the Hoxa9/Meis1 leukemogenic cooperation. 
  • Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. 
  • Follicular mucinosis as a presenting sign of acute myeloblastic leukemia. 
  • Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. 
  • Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission. 
  • Functional changes in human leukemic cell line HL-60. A model for myeloid differentiation. 
  • Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. 
  • Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. 
  • Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia. 
  • Glutathione peroxidase protein. Absence in selenium deficiency states and correlation with enzymatic activity. 
  • Granulocyte colony-stimulating factors and risk of acute myeloid leukemia and myelodysplastic syndrome. 
  • Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. 
  • Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. 
  • HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group. 
  • Has there been progress in the treatment of older patients with acute myeloid leukemia? 
  • Health care utilization and end-of-life care for older patients with acute myeloid leukemia. 
  • Health conditions and quality of life in survivors of childhood acute myeloid leukemia comparing post remission chemotherapy to BMT: a report from the children's oncology group. 
  • Health-related Quality of Life (HR-QOL) and Chronic Health Conditions in Survivors of Childhood Acute Myeloid Leukemia (AML) with Down Syndrome (DS): A Report From the Children's Oncology Group. 
  • Hematopoietic cell transplantation with cord blood for cure of HIV infections. 
  • Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. 
  • High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. 
  • High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). 
  • High-fidelity mRNA amplification for gene profiling. 
  • Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. 
  • Human leukemia antigens: partial isolation and characterization. 
  • Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. 
  • Human thymic epithelial cells produce granulocyte and macrophage colony-stimulating factors. 
  • I and i antigens on normal and leukemic leukocytes. 
  • Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. 
  • Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. 
  • Impetiginous lesions in recurrent AML. 
  • In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. 
  • In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline. 
  • Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. 
  • Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. 
  • Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. 
  • Individualizing treatment decisions for older adults with hematologic malignancies. 
  • Induction chemotherapy in Jehovah's Witnesses with leukaemia. 
  • Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. 
  • Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. 
  • Invasive aspergillosis complicating pandemic influenza A (H1N1) infection in severely immunocompromised patients. 
  • Invasive aspergillosis in pediatric patients. 
  • Is timing everything? 
  • Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. 
  • Isolation of GTP-binding proteins from myeloid HL-60 cells. Identification of two pertussis toxin substrates. 
  • Iterative generalized least squares for meta-analysis of survival data at multiple times. 
  • KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. 
  • Leukemic ascites complicating acute myelomonoblastic leukemia. 
  • Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. 
  • Leukemic relapse presenting as sciatic nerve involvement by chloroma (granulocytic sarcoma). 
  • Leukemic retinopathy. 
  • Lineage Switch Between B-Lymphoblastic Leukemia and Acute Myeloid Leukemia Intermediated by "Occult" Myelodysplastic Neoplasm: Two Cases of Adult Patients With Evidence of Genomic Instability and Clonal Selection by Chemotherapy. 
  • Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. 
  • Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. 
  • Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial). 
  • Long-term outcomes of myeloid growth factor treatment. 
  • Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study. 
  • Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. 
  • Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. 
  • Lymphadenopathy as the primary manifestation of malignant transformation in two patients with severe congenital neutropenia. 
  • MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. 
  • Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. 
  • Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. 
  • Microassay for the photometric quantitation of cell-associated plasminogen activator using a chromogenic tripeptide substrate. 
  • Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects. 
  • Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months. 
  • Mitochondrial Homeostasis in AML and Gasping for Response in Resistance to BCL2 Blockade. 
  • Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD. 
  • Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL-60 cells induced by the glutamine antagonist acivicin. 
  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. 
  • Myelodysplastic syndromes in the United States: an update for clinicians. 
  • Myelodysplastic syndromes. 
  • Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 23 Cases. 
  • Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens. 
  • NCCN Clinical Practice Guidelines Acute myeloid leukemia. 
  • NCCN Practice Guidelines for Acute Myelogenous Leukemia. 
  • NCCN task force report: molecular markers in leukemias and lymphomas. 
  • NF1 inactivation in adult acute myelogenous leukemia. 
  • Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. 
  • Nitric oxide modulation of the growth and differentiation of freshly isolated acute non-lymphocytic leukemia cells. 
  • Nodular subcutaneous abscesses caused by Candida tropicalis. 
  • Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. 
  • Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. 
  • Obesity in pediatric oncology. 
  • Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. 
  • Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. 
  • Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study. 
  • Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. 
  • Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. 
  • Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. 
  • Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. 
  • Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow. 
  • Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. 
  • Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. 
  • Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. 
  • Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. 
  • P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. 
  • PIG-A, DAF and proto-oncogene expression in paroxysmal nocturnal haemoglobinuria-associated acute myelogenous leukaemia blasts. 
  • Patient experiences of acute myeloid leukemia: A qualitative study about diagnosis, illness understanding, and treatment decision-making. 
  • Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. 
  • Patient-reported symptoms and quality of life 
in adults with acute leukemia: a systematic review. 
  • Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. 
  • Perceived Benefits and Barriers to Exercise for Recently Treated Adults With Acute Leukemia 
  • Performance status in elderly patients with acute myeloid leukemia: exploring gene expression signatures of cytokines and chemokines. 
  • Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. 
  • Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. 
  • Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. 
  • Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. 
  • Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. 
  • Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. 
  • Phase I evaluation of diaziquone in childhood cancer. A Pediatric Oncology Group study. 
  • Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. 
  • Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. 
  • Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. 
  • Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. 
  • Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. 
  • Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. 
  • Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. 
  • Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. 
  • Poor Oral Health Linked with Increased Risk of Infectious Complications in Adults with Leukemia. 
  • Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. 
  • Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML. 
  • Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. 
  • Preclinical efficacy of MEK inhibition in Nras-mutant AML. 
  • Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course. 
  • Prediction of a time-to-event trait using genome wide SNP data. 
  • Preparation and characterization of lymphocyte-activating factor (LAF) from acute monocytic and myelomonocytic leukemia cells. 
  • Pretreatment cytokinetic studies in 94 children with acute leukemia. Relationship to other variables at diagnosis and to outcome of standard treatment. 
  • Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. 
  • Prognostic factors in elderly patients with AML and the implications for treatment. 
  • Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. 
  • Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials. 
  • Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. 
  • Prognotic significance of pretreatment proliferative activity in adult acute leukemia. 
  • Progress against childhood cancer: the Pediatric Oncology Group experience. 
  • Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. 
  • Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. 
  • Psychosocial Experiences of Young Adults Diagnosed With Acute Leukemia During Hospitalization for Induction Chemotherapy Treatment. 
  • Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. 
  • Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress. 
  • RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. 
  • Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. 
  • Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. 
  • Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia. 
  • Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014. 
  • Receptor-mediated monocytoid differentiation of human promyelocytic cells by tumor necrosis factor: synergistic actions with interferon-gamma and 1,25-dihydroxyvitamin D3. 
  • Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines. 
  • Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. 
  • Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. 
  • Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. 
  • Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. 
  • Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. 
  • Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. 
  • Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. 
  • Releasing the block: setting differentiation free with mutant IDH inhibitors. 
  • Report of the first case of invasive fungal sinusitis caused by Scopulariopsis acremonium: review of scopulariopsis infections. 
  • Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). 
  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. 
  • Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review. 
  • Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). 
  • Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. 
  • Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). 
  • Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. 
  • Sample size calculation for multiple testing in microarray data analysis. 
  • Schedule and concentration-dependent induction of apoptosis in leukemia cells by nitric oxide. 
  • Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. 
  • Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. 
  • Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. 
  • Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. 
  • Shifting paradigms in the treatment of older adults with AML. 
  • Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia. 
  • Specific receptors for phorbol diesters on freshly isolated human myeloid and lymphoid leukemia cells: comparable binding characteristics despite different cellular responses. 
  • Study Limitations in HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia-Reply. 
  • Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. 
  • Symptom Management and Psychosocial Needs of Adults With Acute Myeloid Leukemia During Induction Treatment: A Pilot Study. 
  • Symptoms, Mobility and Function, and Quality of Life in Adults With Acute Leukemia During Initial Hospitalization. 
  • TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. 
  • Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia. 
  • Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. 
  • Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia. 
  • The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. 
  • The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. 
  • The impact of remission status on patients' experiences with acute myeloid leukemia (AML): an exploratory analysis of longitudinal patient-reported outcomes data. 
  • The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. 
  • The light microscopic demonstration of hydroperoxidase-positive Phi bodies and rods in leukocytes in acute myeloid leukemia. 
  • The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. 
  • The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). 
  • The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. 
  • The unique supportive care needs of a mother with acute myeloid leukemia during treatment. 
  • The use of prophylactic eye drops during high-dose cytosine arabinoside therapy. 
  • Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial. 
  • Transcription interruption may be a common mechanism of c-myc regulation during HL-60 differentiation. 
  • Transient increase in plasma quinidine concentrations during ketoconazole-quinidine therapy. 
  • Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. 
  • Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. 
  • Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study. 
  • Unfavorable prognosis of acute leukemia in infancy. 
  • Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. 
  • Use of ED and hospital services for patients with acute leukemia after induction therapy: one year follow-up. 
  • Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. 
  • WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy. 
  • miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. 
  • t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm? 
• 

  Keywords of People

  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology
  • Yan, Hai, Henry S. Friedman Distinguished Professor of Neuro-Oncology in the School of Medicine, Pathology